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Abstract
Introduction: Signal transducer and activator of transcripton-5a (Stat5a) and its close homologue, Stat5b, mediate
key physiological effects of prolactin and growth hormone in mammary glands. In breast cancer, loss of nuclear
localized and tyrosine phosphorylated Stat5a/b is associated with poor prognosis and increased risk of antiestrogen
therapy failure. Here we quantify for the first time levels of Stat5a and Stat5b over breast cancer progression, and
explore their potential association with clinical outcome.
Methods: Stat5a and Stat5b protein levels were quantified in situ in breast-cancer progression material. Stat5a and
Stat5b transcript levels in breast cancer were correlated with clinical outcome in 936 patients. Stat5a protein was
further quantified in four archival cohorts totaling 686 patients with clinical outcome data by using multivariate
models.
Results: Protein levels of Stat5a but not Stat5b were reduced in primary breast cancer and lymph node metastases
compared with normal epithelia. Low tumor levels of Stat5a but not Stat5b mRNA were associated with poor
prognosis. Experimentally, only limited overlap between Stat5a- and Stat5b-modulated genes was found. In two
cohorts of therapy-naïve, node-negative breast cancer patients, low nuclear Stat5a protein levels were an
independent marker of poor prognosis. Multivariate analysis of two cohorts treated with antiestrogen monotherapy
revealed that low nuclear Stat5a levels were associated with a more than fourfold risk of unfavorable outcome.
Conclusions: Loss of Stat5a represents a new independent marker of poor prognosis in node-negative breast
cancer and may be a predictor of response to antiestrogen therapy if validated in randomized clinical trials.
Introduction
Signal transducer and activator of transcription-5a (Stat5a)
was first identified as “mammary gland factor” [1], and
subsequently, the highly homologous but distinct Stat5b
gene was discovered [2]. Stat5a and Stat5b are activated in
response to hormones or cytokines by phosphorylation of
a tyrosine residue located within structurally identical
motifs near their C-terminal transactivation domains.
Phosphorylated Stat5 molecules undergo functional
dimerization, nuclear translocation, and DNA binding to
modulate expression of target genes that promote mam-
mary epithelial cell survival, proliferation, and differentia-
tion [3-5]. Stat5a and Stat5b are encoded by separate
genes but share greater than 90% amino acid identity.
Despite some overlapping functions, Stat5a and Stat5b
have distinct regulatory features and functions [6-8], as
well as distinct tissue-specific expression patterns [4,5].
Based on gene-knockout studies in mice, pregnancy-asso-
ciated growth and differentiation of normal mammary
epithelia require Stat5a but not Stat5b [4,9]. However,
consistent with partially overlapping functions of Stat5a
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and Stat5b, Stat5b is phosphorylated during pregnancy,
and upregulation of phospho-Stat5b in Stat5a-deficient
mice is associated with restored lactation after repeated
pregnancies [5,10]. Emerging evidence points to critical
involvement of Stat5 transcription factors in the develop-
ment and progression of breast cancer. Current data sup-
port the concept of dual roles of Stat5a/b proteins as
promoters of mammary tumorigenesis, and as suppressors
of the progression of established breast cancer [11,12],
although our knowledge of individual roles of Stat5a and
Stat5b in breast cancer remains rudimentary.
Experimental support for a promoting role of Stat5a in
mammary tumor initiation includes genetic models in
mice in which Stat5a is either suppressed or hyperacti-
vated [13-15]. A function for Stat5a in tumor initiation
may involve proliferative upregulation of cyclin D1
[16,17] and antiapoptotic effects, for instance, through
upregulation of Akt1 [18] or induction of Survivin [19].
Conversely, experimental in vitro data indicate that
Stat5a maintains cellular differentiation and suppresses
epithelial-to-mesenchymal transition and invasive charac-
teristics of human breast cancer cell lines [20-23], and a
positive association between nuclear Stat5a and more
well-differentiated human breast cancer has been
reported [24,25]. Expression of constitutively active
Stat5a promoted breast cancer cell survival and ancho-
rage-independent growth but inhibited migration,
whereas constitutively active Stat5b had little or no effect,
possibly because of its limited capacity to upregulate
Survivin [19]. Furthermore, prolactin-suppression of the
Bcl6 oncogene in human breast cancer cell lines [26] was
preferentially mediated by Stat5a over Stat5b [22]. In
contrast, Stat5b has been reported to contribute to the
progression of established breast cancer. Stat5b but not
Stat5a promoted in vitro migration of ER-negative BT549
and MDA-MB-231 breast cancer cells [27]. In ER-posi-
tive T47D and MCF7 cells, Stat5b was implicated as a
mediator of estrogen-induced proliferation, and a consti-
tutively active Stat5b mutant induced resistance to anti-
estrogens [28]. Collectively, these experimental data
indicate distinct roles of Stat5a and Stat5b in breast
tumor biology.
In healthy human and rodent mammary epithelia out-
side of pregnancy, Stat5a/b is consistently tyrosine phos-
phorylated and transcriptionally active at a basal level [5],
whereas a progressive loss of nuclear-localized, tyrosine-
phosphorylated Stat5a/b (Nuc-pYStat5a/b) has been
observed in invasive and metastatic breast cancer
[22,29,30]. Low levels of Nuc-pYStat5a/b were a strong
independent marker of poor prognosis in node-negative
breast cancer and were also a strong independent marker
associated with antiestrogen therapy failure [29,30].
Importantly, phosphotyrosine motifs surrounding the
conserved amino acid residues Y694 of Stat5a and Y699
of Stat5b are identical and cannot be distinguished by
phosphotyrosine-Stat5 antibodies. Most analyses of Stat5
in breast cancer specimens to date have focused on
detecting either Stat5a or Stat5b or investigated Stat5
without discriminating between Stat5a and Stat5b. As a
result, apparently conflicting lines of evidence have been
reported, based on a few limited studies for associations
between clinicopathologic parameters and levels of Stat5
transcription factors. Furthermore, the mechanisms
underpinning loss of Nuc-pYStat5a/b in breast cancer
remain to be identified, and it is unknown whether
reduced Nuc-pYStat5a/b levels in breast cancer may in
part reflect reduced levels of Stat5a and/or Stat5b protein
expression.
Several studies have reported low levels of Stat5 protein
in invasive breast cancer. First, only 34% of 517 invasive
breast cancer cases were positive for epithelial cell Stat5
expression, as measured by immunohistochemistry, and
nuclear Stat5 was detected in as few as 18 (3%) of cases
[31]. In that study, undetectable Stat5 protein was asso-
ciated with poor clinical outcome in ER-positive patients
and poor response to post-relapse antiestrogen therapy
[31].
Second, cytoplasmic or nuclear Stat5a was detected in
17% of 30 cases of breast adenocarcinomas compared with
nearly 100% positive expression in normal tissue [25]. In
contrast, our initial study of a breast cancer progression
material by using a pan-Stat5a/b antibody indicated that
malignant breast tumors generally remained positive for
expression of Stat5 protein across the progression series,
although quantification was not attempted, and the anti-
body used did not discern between Stat5a and Stat5b [29].
Other groups reported high frequencies of nuclear Stat5a
expression in breast adenocarcinomas, ranging from 48%
to 74% of cases [24,32]. Collectively, these discrepant and
incomplete data warrant a more systematic effort to quan-
tify Stat5a or Stat5b protein expression during human
breast cancer progression relative to normal breast tissue.
With selective Stat5a and Stat5b antibodies and immu-
nofluorescence detection on the Automated Quantitative
Analysis (AQUA) platform [33,34], Stat5a and Stat5b
protein levels were quantified in breast cancer progres-
sion material. Unexpectedly, the analyses revealed fre-
quent and selective loss of nuclear as well as total Stat5a
protein in invasive breast cancer and lymph node metas-
tases, whereas expression of Stat5b remained unchanged.
Low transcript levels for Stat5a but not Stat5b in breast
cancer specimens were associated with poor clinical out-
come. Based on four independent clinical materials,
reduced levels of nuclear-localized Stat5a were prognos-
tic of unfavorable breast cancer outcome in patients who
did not receive systemic adjuvant therapy and were asso-
ciated with elevated risk of failure of antiestrogen therapy
in patients. Loss of Stat5a protein may represent a new
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mechanism contributing to the reported frequent loss of
Nuc-pYStat5a/b during breast cancer progression.
Materials and methods
Paraffin-embedded breast tumor specimens
Five independent and deidentified clinical cohorts of
breast cancer tissues, represented as formalin-fixed and
paraffin-embedded whole tissue sections or tissue
microarrays, were evaluated. The research use of tissues
was approved by the ethics committee of the respective
institutions, and informed consent was waived as anon-
ymous archival tissue specimens were used. Clinical
information was not available for progression Material I.
Patient demographics and clinical features of Materials
III, IV, V, and VI are presented in Table 1.
Material I was a breast cancer progression tissue array
constructed by using cutting-edge matrix assembly [35]
and represented 180 unmatched patient specimens,
including 40 normal breast tissues, 20 ductal carcinoma
in situ (DCIS), 100 invasive ductal carcinomas (IDCs),
and 20 lymph node breast cancer metastases [22]. Tissues
were obtained from Thomas Jefferson University Hospi-
tal archives. The array contained 59% estrogen receptor
(ER)-positive, 42% progesterone receptor (PR)-positive,
and 20% Her2-positive cases, as determined by patholo-
gist scoring of standard DAB-chromogen immunohisto-
chemistry (DAB-IHC). Stat5a scores, detected by
immunofluorescence and quantified by automated quan-
titative analysis (AQUA), were obtained for 126 cases,
and Stat5b AQUA scores were obtained for 116 cases.
Material III, obtained through the National Cancer
Institute Cooperative Breast Cancer Tissue Resource,
comprised whole tissue sections from patients with
node-negative IDC who did not receive adjuvant systemic
therapy (n = 233). Nuclear Stat5a (Nuc-Stat5a) scores
were calculated through pathologist scoring of traditional
DAB-IHC and obtained for 223 tumor specimens.
Material IV was a breast cancer tissue microarray (0.6-
mm cores) from Yale University pathology archives,
representing 291 node-negative IDC patients who did
not receive adjuvant systemic therapy [30]. Nuc-Stat5a
AQUA scores were obtained for 239 tumors.
Material V comprised whole tissue sections from tumors
of node-negative IDC patients who received adjuvant hor-
mone monotherapy (n = 75). Specimens were obtained
through the National Cancer Institute Cooperative Breast
Cancer Tissue Resource. Nuc-Stat5a DAB-IHC scores
were obtained for 73 tumor specimens.
Material VI was a 0.6-mm tumor tissue core microarray
from a random series of breast cancer patients identified
through the Alberta Cancer Registry (Calgary, Alberta,
Canada) who received adjuvant hormone monotherapy for
up to 60 months (average, 30 months) [30]. The array was
constructed in triplicate from tumors of 50 patients who
died of breast cancer and 50 patients with greater than 5-
year follow-up without breast cancer recurrence. AQUA
analysis yielded informative data on Nuc-Stat5a for 71
cases. Stat5a and Stat5b mRNA expression levels were
evaluated in the context of clinical outcome in RNA
microarray datasets (Material II) compiled from public
repositories, Gene Expression Omnibus [36] and ArrayEx-
press [37], as described previously [38].
Prolactin-induced Stat5a and Stat5b gene profiles
Adenoviral delivery of Stat5a and Stat5b was performed as
previously described [21,39]. In brief, confluent MCF7
cells were infected with adenovirus in serum-free media
(1 × 106 cells/well; multiplicity of infection (MOI) = 40)
for 90 minutes at 37°C and cultured in regular growth
media for 24 hours. Cells were serum starved for 16 hours
before treatment with or without 10 nM PRL for 20 min-
utes (protein detection) or 4 hours (mRNA analysis).
Stat5a and Stat5b expression and phosphorylation were
determined by standard immunoblotting. Genome-wide
transcript profiling of mRNA (RNeasy Kit; Qiagen Inc.,
Valencia, CA, USA) was performed in triplicate by the
KCC Genomics Core. RNA was validated by using the
Agilent Bioanalyzer (Santa Clara, CA, USA) followed by
cDNA synthesis and labeling for microarray expression
profiling by using the HuGene 1.0 ST Array (Affymetrix,
Santa Clara, CA, USA; GEO: GSE37781 [40]).
Quantification of Stat5a and Stat5b by automated
quantitative analysis (AQUA)
Rabbit polyclonal antisera specific for Stat5a and Stat5b
were generated against unique epitopes of each protein, as
previously described [5]. Antibody specificity was verified
by cross-immunoprecipitation followed by immunoblot-
ting and by immunohistochemistry on formalin-fixed, par-
affin-embedded breast tissues in the presence or absence
of blocking immunizing peptide. Immunofluorescent
staining of Stat5a or Stat5b for AQUA analysis was per-
formed on a Dako Autostainer by following a reported
protocol [30] with Stat5a (1:8,000) or Stat5b (1:4,000) anti-
sera used for primary detection. The AQUA/PM2000 plat-
form (HistoRx, New Haven, CT, USA) [33] was used as
previously described [22,30] to quantify cellular and
nuclear levels of Stat5a or Stat5b (Cy5) within tumor tis-
sue, as defined by cytokeratin-positive (FITC/Alexa-488)
and nuclei-positive (DAPI) mapping. Cases not interpreta-
ble by AQUA because of loss of histospots or insufficient
staining quality or tumor sampling were excluded [33].
Detection of Stat5a by DAB-chromogen
immunohistochemistry
DAB chromogen immunohistochemistry (DAB-IHC) for
Stat5a and Stat5b was performed by following the pre-
viously described protocol by using a Dako Autostainer
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Table 1 Characteristics of patients in Materials III, IV, V, and VI
Material III
prognosis (n = 233)
Material IV





antiestrogen (n = 97)
Number % Number % Number % Number %
Center Fox Chase 64 27 - - 19 25 - -
Kaiser 79 34 - - 35 47 - -
Univ of Miami 30 13 - - 11 15 - -
Washington Univ 60 26 - - 10 13 - -
Race Asian 1 0.4 0 0 1 1.3 - -
Black 16 7 3 1 6 8 - -
White 216 93 287 99 67 89 - -
Other 0 0 1 0.3 1 1.3 - -
Age (years) < 50 42 18 86 30 9 12 6 6
≥50 191 82 205 70 66 88 91 94
Size (cm) < 2 117 50 114 39 41 55 39 40
≥2 to < 5 107 46 133 46 34 45 43 44
≥5 9 4 33 11 0 0 11 11
Missing 0 0 11 4 0 0 4 4
Grade 1 61 26 67 23 17 23 14 14
2 104 45 137 47 45 60 47 48
3 68 29 48 16 13 17 32 33
Missing 0 0 39 13 0 0 4 4
ER status Negative 44 19 97 33 1 1.3 11 11
Positive 186 80 163 56 72 96 80 82
Missing 3 1.3 31 11 2 3 6 6
PR status Negative 65 28 103 35 9 12 - -
Positive 122 52 151 52 56 75 - -
Missing 46 20 37 13 10 13 - -
ER/PR status Negative 44 19 68 23 1 1.3 12 12
Positive 178 76 192 66 72 96 83 86
Missing 11 5 31 11 2 3 2 2
HER2 status Negative - - 217 75 - - 77 79
Positive - - 33 11 - - 13 13
Missing - - 41 14 - - 7 7
Nodal status Negative 233 100 291 100 73 100 42 43
Positive 0 0 0 0 0 0 42 43
Missing 0 0 0 0 0 0 13 13
Chemotherapy Untreated 233 100 - - 75 100 97 100
Treated 0 0 - - 0 0 0 0
Missing 0 0 - - 0 0 0 0
Hormone therapy Untreated 233 100 - - 0 0 0 0
Treated 0 0 - - 75 100 97 100
Radiation therapy Untreated 187 80 - - 48 64 36 37
Treated 46 20 - - 27 36 59 61
Missing 0 0 - - 0 0 2 2
Stat5a status Low 30 13 200 69 9 12 24 25
High 193 83 39 13 64 85 47 48
Missing 10 4 52 18 2 3 26 27
CSS events Number 52 22 107 37 10 13 56 58
TTR events Number 56 24 - - 13 17 60 62
Evaluable subjects for multivariate Number 218 94 190 65 73 97 55 57
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Plus (Dako, Carpinteria, CA, USA) with the following
modifications [29,30]. Antigen retrieval was performed
by using the DAKO PT-module with citric acid buffer
(pH 6.0). Stat5a (1:8,000) or Stat5b (1:4,000) antibody
was incubated with tissue slides for 30 minutes at room
temperature. Transcriptionally active Stat5a, defined by
nuclear localization of the protein (Nuc-Stat5a), was
identified by a pathologist blinded to clinical outcome.
Control experiments validating nuclear localization of
the Stat5a protein in response to prolactin were per-
formed by using viable surgically removed healthy
human breast tissues obtained from Thomas Jefferson
University Hospital under IRB-approved protocols.
Explants were cultured ex vivo at 37°C in RPMI media
containing 10% FBS and 1 mM sodium pyruvate, with or
with 100 nM human prolactin for 1 hour and subse-
quently formalin fixed, paraffin embedded, and sectioned.
Standard DAB-IHC was performed as described pre-
viously [29,30].
Statistical methods
Affymetrix HuGene ST 1.0 expression-signal estimates
were computed by using iterPLIER in Affymetrix Expres-
sion Console version 1.1. Genes represented by multiple
probesets were averaged, and expression values were
scaled to the probeset with the maximal variance for that
gene. Low-signal genes were filtered out by retaining
genes expressed above the 25th percentile on at least one
array. Approximately 85% of genes were retained and
evaluated for differential expression between Stat5a or
Stat5b-expressing cells in the presence or absence of pro-
lactin by using Significance Analysis for Microarrays with
25% false discovery rate and 1.25 minimum fold-change
cutoffs.
One-way ANOVA with Dunnett T3 pairwise post hoc
test (SPSS v15.0; SPSS Inc, Chicago, IL, USA) was used
to compare levels of Stat5a or Stat5b between breast his-
tology groups in progression Material I. Clinical end
points for survival analyses in Materials III, V, and VI
were breast cancer-specific survival (CSS) and time-to-
recurrence (TTR) of either local or distant disease,
according to consensus definitions [41]. For Material IV,
only CSS was available. Statistical software R (v2.11.1)
[42] determined optimal cutpoints for low and high
Stat5a-expressing tumors as a function of patient survival
in all materials. Survival analyses were conducted by
using Kaplan-Meier plots, log-rank test, and adjusted
Cox regression when proportional hazard assumption
passed (assessed globally by using a Wald goodness-of-fit
c2 test for each cohort and outcome multivariate model)
or adjusted Weibull regression when proportional hazard
assumption failed (SAS v9.2; SAS Institute, Cary, NC,
USA). When available, variables included in the adjusted
models were tumor grade, tumor size, lymph node status,
ER/PR expression, Her2 status, and Nuc-Stat5a.
Results
Levels of nuclear-localized Stat5a but not Stat5b are
diminished during breast cancer progression
To investigate whether previously reported reduced
levels of Nuc-pYStat5a/b during breast cancer progres-
sion could in part be caused by loss of Stat5a or Stat5b
protein expression, a breast tissue progression array
(Material I) that included normal breast, ductal carci-
noma in situ (DCIS), invasive ductal carcinoma (IDC),
and lymph node metastases, was stained for Stat5a or
Stat5b with immunofluorescence labeling and quantified
with AQUA (Figure 1). Levels of Nuc-Stat5a were mark-
edly reduced during breast cancer progression, with sig-
nificant loss of Nuc-Stat5a expression in IDC (P <
0.001) and greatest loss in lymph node metastases (P <
0.001; Figure 1A, C). Interestingly, loss of Nuc-Stat5a
over progression occurred in parallel with our previously
reported loss of Nuc-pYStat5a/b in the same breast-pro-
gression tissue array (Figure 1C) [30]. In contrast, Nuc-
Stat5b remained detectable, and levels did not change
over progression (Figure 1B, C). These quantitative in
situ data provided novel information indicating that
levels of Nuc-Stat5a, but not Nuc-Stat5b, are reduced
over breast cancer progression.
To verify lack of cross-reactivity between the Stat5a and
Stat5b polyclonal antibodies developed to the unique
C-termini of Stat5a and Stat5b [5], the two proteins were
individually immunoprecipitated from SKBR3 breast
cancer cell lysates and resolved by gel electrophoresis.
Cross-immunoblotting with the same Stat5a-specific or
Stat5b-specific antibodies demonstrated specificity of each
antibody (see Additional File 1, panel A). Immunoblotting
Table 1 Characteristics of patients in Materials III, IV, V, and VI (Continued)
Mean (Range) Mean (Range) Mean (Range) Mean (Range)
Stat5a score - 32 (0-90) 653 (175-2,099) 34.1 (0-80) 1,949 (727-4,626)
Date of diagnosis Year 1974-1990 1953-1980 1986-1996 1990-2000
Age at diagnosis Years 62.3 (31-88) 57.3 (24-86) 64.6 (43-88) 69.8 (38-89)
Tumor size cm 2.1 (0.6-7.5) 2.5 (0.4-11) 1.9 (0.5-4.5) 2.7 (0.4-11)
Follow-up Months 126 (3-326) 160 (1-425) 117 (10-195) 41 (4-143)
ER, estrogen receptor; PR, progesterone receptor; SD, standard deviation.
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Stat5a or Stat5b immunoprecipitations with a pan-Stat5a/
b antibody further confirmed specificity by detecting only
single bands in each immunoprecipitation corresponding
to the slightly slower-migrating Stat5a band (94 kDa) or
the slightly faster migrating Stat5b band (92 KDa). Anti-
body specificity for detection of Stat5a or Stat5b was
further extended to immunohistochemistry on formalin-
fixed, paraffin-embedded tissue in the presence or absence
of blocking peptides representing the unique immunogens.
Detection of Stat5a or Stat5b was reduced in peptide-
competed conditions compared with control conditions
(see Additional File 1, panel B). In the absence of selec-
tive phospho-tyrosine-Stat5a or phospho-tyrosine-Stat5b
antibodies, levels of nuclear Stat5a or nuclear Stat5b can
be measured as a proxy for tyrosine-phosphorylated,
nuclear-localized and transcriptionally active protein.
After ex vivo prolactin stimulation of viable human breast
tissue explants, prolactin preferentially increased levels of
Figure 1 Nuclear localization of Stat5a (Nuc-Stat5a) is lost during breast cancer progression. (A) Detection of nuclear-localized Stat5a in
Material I with immunofluorescence and quantified with AQUA revealed a significant reduction in Nuc-Stat5a protein in invasive ductal
carcinoma (IDC; n = 66) and lymph node metastases (n = 19) when compared with normal breast tissue (n = 23) and ductal carcinoma in situ
(DCIS; n = 18). (B) Levels of nuclear localized Stat5b (Nuc-Stat5b) remained unchanged between normal (n = 24), DCIS (n = 12), IDC (n = 67),
and lymph node metastases (n = 13) in the same breast progression array (Material I). (C) Representative images of Stat5a, Stat5b, and pY-Stat5a/
b detected with immunofluorescence in normal human breast tissue and lymph node metastases (Material I). Stat5a, Stat5b, pY-Stat5a/b, red
(Cy5); cytokeratin, green (FITC); nuclei, blue (DAPI). (D) Stat5a protein (upper panels) translocated to the nucleus after ex vivo prolactin stimulation
of human breast tissue explants, whereas prolactin induced only minimal nuclear localization of Stat5b protein (middle panels). Corresponding
with enrichment of nuclear Stat5a protein in response to prolactin, tyrosine-phosphorylated Stat5a/b (pY-Stat5a/b) was induced in the nuclei of
the same breast tissue after ex vivo stimulation with prolactin (lower panels). (E, F) Levels of total cellular Stat5a protein (E), but not total cellular
Stat5b protein (F), were significantly reduced over breast cancer progression (Material I). (G, H) Stat5a mRNA expression levels in human breast
tumor tissue (Material II) were associated with relapse-free survival (G), whereas Stat5b mRNA expression levels were not associated with relapse-
free survival (H). Statistical differences (ANOVA, Dunnett T3 post hoc test) in levels of nuclear and total cellular Stat5a or Stat5b over breast cancer
progression in relation to normal histologic type are indicated. ***p < 0.001; *p < 0.05. AQUA, Automated Quantitative Analysis; DCIS, ductal
carcinoma in situ; IDC, invasive ductal carcinoma; IQR, interquartile range; LN Met, lymph node metastasis.
Peck et al. Breast Cancer Research 2012, 14:R130
http://breast-cancer-research.com/content/14/5/R130
Page 6 of 16
Stat5a protein in the nucleus of normal luminal epithelial
cells, but was less effective at enhancing nuclear levels of
Stat5b protein (Figure 1D). Corresponding to enhanced
levels of nuclear Stat5a in response to prolactin, tyrosine-
phosphorylated Stat5a/b was highly enriched in the
epithelial cell nuclei of the same prolactin-stimulated
tissues (Figure 1D).
Total cellular expression of Stat5a but not Stat5b protein
is suppressed over breast cancer progression
The reduced levels of nuclear-localized Stat5a protein in
invasive breast cancer and lymph node metastases are con-
sistent with our previous reports showing a loss of Nuc-
pYStat5a/b [29,30]. We previously showed that levels of
the Jak2 phosphatase, PTP1B, were inversely correlated
with Nuc-pYStat5a/b levels in human breast cancer and
that PTP1B suppressed prolactin-induced Stat5a phos-
phorylation levels [43], suggesting that low levels of Nuc-
pYStat5a/b in breast cancer may in part be due to reduced
phosphorylation of Stat5a. To determine whether the
observed reduction in Nuc-Stat5a levels could be attribu-
ted to a reduction of total cellular Stat5a protein, we quan-
tified levels of total cellular Stat5a protein by using AQUA
within the breast tissue progression array. Interestingly,
total cellular levels of Stat5a protein were significantly
reduced from normal epithelia to invasive and metastatic
breast cancer (P < 0.001; Figure 1E). In contrast, total
cellular Stat5b levels remained unchanged across the pro-
gression material (Figure 1F). We conclude that loss of
Nuc-Stat5a in invasive breast cancer and metastases
reflects, in part, loss of total cellular expression of Stat5a
protein and is not simply a result of reduced tyrosine
phosphorylation and nuclear translocation or due to
increased nuclear exclusion of Stat5a.
mRNA levels for Stat5a but not Stat5b are prognostic of
breast cancer relapse
Tumor levels of Stat5a and Stat5b mRNA in a cohort of
936 patients with available outcome data were then inter-
rogated to determine whether expression of Stat5a or
Stat5b in primary invasive breast cancer was associated
with clinical outcome. Interestingly, patients whose
tumors were in the lowest quartile of Stat5a mRNA
expression levels were associated with reduced time to
breast cancer relapse, whereas the highest quartile of
Stat5a mRNA expression levels associated with longer
time to relapse (Figure 1G). However, Stat5b mRNA
levels were not informative about the risk of breast
cancer relapse (Figure 1H).
Stat5a and Stat5b modulate different gene-transcription
profiles in breast cancer
Despite high homology, transcript profiles were shown
to differ significantly after selective knockdown of either
Stat5a or Stat5b expression by using siRNA in BaF3
cells, a murine pro-B cell line [44]. In MCF-7 human
breast cancer cells, expression of selected genes also dif-
fered after stable introduction of constitutively active
Stat5a or Stat5b [19].
More directly and in an unbiased manner to determine
the degree of overlap of immediate-early transcripts
modulated by Stat5a or Stat5b in MCF-7 cells, we per-
formed genome-wide transcript profiling after transient
overexpression of Stat5a or Stat5b by using adenoviral
gene delivery, followed by a brief 4-hour exposure to
human prolactin. This experimental strategy avoids basal
activation, because in these cells, exogenous wild-type
Stat5a or Stat5b remains unphosphorylated until prolactin
stimulation (see Additional File 2). Consistent with diver-
gent target genes for Stat5a and Stat5b, genome-wide tran-
script profiling revealed that less than 10% of the top 150
modulated genes were common (see Additional File 3).
Nuclear localized Stat5a is an independent marker of
prognosis in node-negative breast cancer
Based on our observations that Stat5a but not Stat5b
mRNA levels correlated with breast cancer outcome and
that Stat5a protein is selectively reduced over breast can-
cer progression, we evaluated Stat5a protein levels with
immunohistochemistry in formalin-fixed, paraffin-
embedded archival breast tumor tissues with clinical out-
come. We first evaluated expression of Nuc-Stat5a by
using DAB-IHC on whole tissue sections in node-
negative breast cancer from patients who did not receive
any systemic adjuvant treatment (Material III). Survival
analyses evaluated time to recurrence (TTR) and cancer-
specific survival (CSS). Low levels of Nuc-Stat5a were
associated with increased risk of breast cancer recurrence
(TTR; log-rank, P = 0.003; n = 223; Figure 2A; univariate
Weibull regression hazard ratio (HR) = 2.60 (1.36, 4.96),
P = 0.004; n = 218, see Additional File 4). Importantly,
low expression of Nuc-Stat5a also was associated with
poor breast cancer-specific survival (CSS; log-rank P =
0.007; n = 223, Figure 2B; univariate Weibull regression
HR = 2.35 (1.20, 4.58); P = 0.012; n = 218; Table 2). To
validate these data, we analyzed levels of Nuc-Stat5a with
immunofluorescence and quantified expression with
AQUA in a tissue microarray from an independent
cohort of adjuvant therapy-naïve, node-negative breast
cancer patients (Material IV). Low levels of Nuc-Stat5a
(Figure 2C) predicted poor breast cancer survival in
Material IV (CSS; log-rank P = 0.021; n = 239, Figure
2D; univariate Weibull regression HR = 2.13 (1.01, 4.49),
P = 0.047; n = 190, Table 2). TTR data were not available
for Material IV.
Nuc-Stat5a remained an independent marker of disease
prognosis in multivariate analyses in both Materials III
and IV. When adjusting for standard clinical and
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pathologic markers in Material III, patients with low
Nuc-Stat5a had an adjusted 2.5-fold increased risk of
disease recurrence (TTR; multivariate Weibull regres-
sion HR = 2.55 (1.31, 4.98), P = 0.006; n = 218, Addi-
tional File 4) and a 2.3-fold greater risk of dying of
breast cancer (CSS; multivariate Weibull regression
HR = 2.34 (1.16, 4.71), P = 0.018; n = 218; Table 2).
Likewise, in Material IV, AQUA-quantified Nuc-Stat5a
was an independent prognostic indicator of breast can-
cer-specific survival, as reflected in a 2.2-fold increased
risk of death (CSS; multivariate Weibull regression
HR = 2.15 (1.02, 4.55), P = 0.045; n = 190; Table 2). We
found comparable effect sizes in two separate cohorts
and by two analytic approaches, and conclude that
Figure 2 Loss of nuclear Stat5a (Nuc-Stat5a) predicts unfavorable breast cancer prognosis. (A, B) Nuclear localization of Stat5a was
detected with standard DAB IHC and pathologist review of whole-tissue sections in Material III. Kaplan-Meier analysis indicated that patients with
low levels of Nuc-Stat5a had (A) reduced time-to-recurrence (TTR) of breast cancer and (B) poor breast cancer-specific survival (CSS). (C, D)
Nuclear localization of immunofluorescently labeled Stat5a was quantified by AQUA analysis in a tissue microarray of node-negative breast
cancer. (C) Representative immunofluorescent images of high and low Stat5a expression in invasive ductal carcinoma. (D) Quantitation of nuclear
levels of Stat5a by AQUA revealed by Kaplan-Meier analysis that loss of Nuc-Stat5a is prognostic of poor breast cancer-specific survival (CSS) in
Material IV. Censored cases (+) and number of patients per group are indicated.
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Nuc-Stat5a is an independent prognostic marker of out-
come in patients with lymph node-negative breast
cancer.
When patients who received radiation therapy were
excluded from these analyses, smaller sample sizes lim-
ited the power, but effect sizes associated with Nuc-
Stat5a were unchanged. Further, Nuc-Stat5a remained
an independent marker of prognosis when radiation
therapy was included in multivariate analyses (data not
shown).
Loss of nuclear Stat5a is associated with unfavorable
outcome in antiestrogen-treated breast cancer patients
To determine whether Nuc-Stat5a may be a predictor of
outcome in patients treated with antiestrogen therapy, we
first analyzed Nuc-Stat5a expression levels by DAB-IHC
and pathologist scoring of whole tissue sections from a
cohort of node-negative breast cancer patients who
received adjuvant antiestrogens and did not receive che-
motherapy (Material V). The absence of detectable Nuc-
Stat5a in these tumors indicated a significantly increased
risk of breast cancer-specific death (CSS; log-rank
P < 0.001; n = 73; Figure 3A; univariate Cox regression
HR = 6.73 (1.88, 24.05); P = 0.003; n = 73). Patients with
undetectable Nuc-Stat5a were also at an increased risk of
breast cancer recurrence (TTR; log-rank P = 0.003; n = 73;
Figure 3B; univariate Cox regression HR = 5.08 (1.52,
17.01); P = 0.008; n = 73). Multivariate analysis of this
cohort revealed that Nuc-Stat5a remained an independent
marker of patient outcome after adjustment for other
tumor parameters both by CSS (multivariate Cox regres-
sion HR = 4.19 (1.13, 15.48); P = 0.032; n = 73) and by
TTR (multivariate Cox regression HR = 4.27 (1.20, 15.19);
P = 0.025; n = 73). ER/PR status was not included in the
multivariate model because only one tumor was ER/PR
negative.
Analysis of Nuc-Stat5a expression as a function of
survival was then performed in an independent tissue
microarray of tumors, which included those from both
node-negative and node-positive patients who were also
treated exclusively with antiestrogen monotherapy
(Material VI). Nuc-Stat5a was detected with immuno-
fluorescence and quantified with AQUA. Patients whose
tumors expressed low levels of Nuc-Stat5a were at
Table 2 Univariate and multivariate survival analyses of breast cancer-specific survival (CSS) in Materials III and IV
Material III CSS (n = 218) Multivariate adjusted (Weibull) Univariate unadjusted (Weibull)
Variable n Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Grade 1 57 1 - 1 -
2 95 1.01 (0.45 to 2.26) 0.977 1.33 (0.62 to 2.85) 0.472
3 66 1.59 (0.65 to 3.87) 0.306 1.90 (0.88 to 4.08) 0.102
Size < 2 cm 108 1 - 1 -
2 to ≥ 5 cm 101 1.59 (0.82 to 3.08) 0.166 1.88 (1.03 to 3.45) 0.041
> 5 cm 9 2.38 (0.74 to 7.60) 0.145 2.86 (0.94 to 8.76) 0.065
ER/PR status Neg 43 1 - 1 -
Pos 175 1.49 (0.68 to 3.26) 0.321 0.87 (0.45 to 1.70) 0.688
Stat5a Low (0) 30 2.34 (1.16 to 4.71) 0.018 2.35 (1.20 to 4.58) 0.012
High (> 0) 188 1 - 1 -
Global test for PH assumption: c2 (4) = 17.18; P = 0.0018.
Material IV CSS (n = 190) Multivariate adjusted (Weibull) Univariate unadjusted (Weibull)
Variable n Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Grade 1 42 1 - 1 -
2 110 1.55 (0.84 to 2.84) 0.162 1.42 (0.77 to 2.59) 0.258
3 38 1.11 (0.50 to 2.47) 0.797 1.10 (0.52 to 2.35) 0.801
Size < 2 cm 71 1 - 1 -
2 to ≥5 cm 98 2.10 (1.19 to 3.72) 0.011 2.01 (1.14 to 3.55) 0.016
≥5 cm 21 3.48 (1.61 to 7.54) 0.002 3.09 (1.45 to 6.58) 0.004
ER/PR status Neg 41 1 - 1 -
Pos 149 0.93 (0.49 to 1.75) 0.824 0.91 (0.52 to 1.59) 0.738
Her2 status Neg 166 1 - 1 -
Pos 24 1.02 (0.47 to 2.20) 0.963 0.97 (0.48 to 1.96) 0.939
Stat5a Low (< 881) 158 2.15 (1.02 to 4.55) 0.045 2.13 (1.01 to 4.49) 0.047
High (≥881) 32 1 - 1 -
Global test for PH assumption: c2(5) = 10.05; P = 0.074.
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markedly increased risk of antiestrogen treatment failure
in this independent material. Risk of death of breast
cancer was significantly increased in patients with low
levels of Nuc-Stat5a (CSS log-rank P = 0.025; n = 71;
Figure 3C; univariate Cox regression HR = 2.75 (1.33,
5.69); P = 0.006; n = 55; Table 3). Univariate Cox
regression also revealed a significant increased risk of
breast cancer recurrence in these patients (TTR univari-
ate Cox regression HR = 2.15 (1.06, 4.35); P = 0.033;
n = 55), although despite a clear separation of Kaplan-
Meier curves, log-rank analysis did not reach statistical
significance (TTR log-rank P = 0.11; n = 71; Figure 3D).
Figure 3 Low levels of nuclear Stat5a (Nuc-Stat5a) predict poor response to antiestrogen therapy. (A, B) Nuc-Stat5a was detected by
DAB-chromogen IHC and pathologist scoring of whole-tissue sections from node-negative breast cancer patients treated with antiestrogen
monotherapy (Material V). The lack of nuclear localization of Stat5a predicted (A) poor breast cancer-specific survival (CSS) and (B) reduced time-
to-recurrence (TTR) of breast cancer. (C, D) Nuc-Stat5a expression levels were measured with immunofluorescence and quantified with AQUA in
node-negative and -positive breast cancer patients treated with antiestrogen monotherapy (Material VI). Low levels of Nuc-Stat5a were predictive
of (C) poor cancer-specific survival (CSS) and (D) reduced TTR of breast cancer. Kaplan-Meier plots with censored cases (+) and number of
patients per group indicated.
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Table 3 Univariate and multivariate Cox regression survival analysis of breast cancer-specific survival (CSS) and time
to recurrence (TTR) as a function of Nuc-Stat5a in breast cancer patients treated with antiestrogen monotherapy
(Materials V and VI)
Material V CSS (n = 73) Multivariate adjusted (Cox) Univariate unadjusted (Cox)
Variable n Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Grade 1 17 1 - 1 -
2 43 3.42 (0.42 to 27.87) 0.251 3.74 (0.46 to 30.52) 0.218
3 13 2.60 (0.23 to 29.30) 0.438 3.32 (0.30 to 36.66) 0.327
Size < 2 cm 40 1 - 1 -
≥2 to ≥5 cm 33 4.29 (0.86 to 21.38) 0.075 5.79 (1.23 to 27.26) 0.026
Stat5a Low (0) 9 4.19 (1.13 to 15.48) 0.032 6.73 (1.88 to 24.05) 0.003
High (> 0) 64 1 - 1 -
Global test for PH assumption: c2(3) = 1.67; P = 0.64.
Material V TTR (n = 73) Multivariate adjusted (Cox) Univariate unadjusted (Cox)
Variable n Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Grade 1 17 1 1
2 43 1.20 (0.30 to 4.81) 0.794 1.27 (0.32 to 5.04) 0.729
3 13 1.59 (0.31 to 8.22) 0.581 1.87 (0.37 to 9.39) 0.448
Size < 2 cm 40 1 1
≥2 to ≥5 cm 33 1.63 (0.49 to 5.43) 0.429 2.24 (0.73 to 6.86) 0.158
Stat5a Low (0) 9 4.27 (1.20 to 15.19) 0.025 5.08 (1.52 to 17.01) 0.008
High (> 0) 64 1 1
Global test for PH assumption: c2(3) = 1.47; P = 0.69.
Material VI CSS (n = 55) Multivariate adjusted (Cox) Univariate unadjusted (Cox)
Variable n Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Grade 1 8 1 - 1 -
2 28 3.48 (0.91 to 13.31) 0.068 1.11 (0.36 to 3.41) 0.855
3 19 2.83 (0.65 to 12.28) 0.164 2.25 (0.73 to 6.91) 0.158
Size < 2 cm 24 1 - 1 -
2 to ≥5 cm 26 3.51 (1.26 to 9.74) 0.016 4.22 (1.76 to 10.13) 0.001
≥5 cm 5 8.54 (1.92 to 37.94) 0.005 6.94 (2.01 to 24.00) 0.002
LN status Neg 29 1 - 1 -
Pos 26 4.72 (1.90 to 11.74) < 0.001 4.30 (1.98 to 9.33) < 0.001
ER/PR status Neg 8 1 - 1 -
Pos 47 0.73 (0.22 to 2.38) 0.597 0.37 (0.16 to 0.86) 0.021
Her2 status Neg 48 1 - 1 -
Pos 7 2.87 (0.92 to 8.96) 0.070 3.07 (1.23 to 7.63) 0.016
Stat5a Low (< 1,454) 16 4.95 (1.87 to 13.06) 0.001 2.75 (1.33 to 5.69) 0.006
High (≥1,454) 39 1 - 1 -
Global test for PH assumption: c2(6) = 3.19; P = 0.78.
Material VI TTR (n = 55) Multivariate adjusted (Cox) Univariate unadjusted (Cox)
Variable n Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Grade 1 8 1 - 1 -
2 28 1.17 (0.37 to 3.72) 0.794 0.87 (0.31 to 2.41) 0.783
3 19 1.24 (0.33 to 4.68) 0.746 1.98 (0.71 to 5.55) 0.191
Size < 2 cm 24 1 - 1 -
2 to ≥5 cm 26 3.38 (1.30 to 8.80) 0.013 3.75 (1.67 to 8.43) 0.001
≥5 cm 5 8.17 (2.26 to 29.50) 0.001 6.91 (2.27 to 21.06) < 0.001
LN status Neg 29 1 - 1 -
Pos 26 3.46 (1.57 to 7.64) 0.002 3.42 (1.67 to 7.01) < 0.001
ER/PR status Neg 8 1 - 1 -
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In multivariate analysis adjusting for tumor size, tumor
grade, lymph node status, ER/PR status, and Her2 over-
expression, Nuc-Stat5a remained an independent marker
of survival in Material VI, predicting a fivefold increased
risk of breast cancer-related death (CSS; multivariate
Cox regression HR = 4.95 (1.87, 13.06); P = 0.001; n =
55; Table 3). Positive node status (CSS; multivariate Cox
regression HR = 4.72 (1.90, 11.74); P < 0.001; n = 55)
and tumor size (CSS; multivariate Cox regression tumor
size 2 to < 5 cm; HR = 3.51 (1.26, 9.74); P = 0.016 and
tumor size ≥5 cm; HR = 8.54 (1.92, 37.94); P = 0.005;
n = 55) were also independent predictors of survival
(Table 3). Although tumors with low Nuc-Stat5a
trended toward earlier breast cancer recurrence, TTR
did not reach statistical significance in multivariate ana-
lysis of Material VI (TTR; multivariate Cox regression
HR = 2.14 (0.89, 5.12); P = 0.087; n = 55). Collectively,
based on two independent cohorts of patients treated
with antiestrogen therapy alone, low levels of Nuc-
Stat5a were in both cohorts associated with elevated risk
of failure of antiestrogen treatment. These initial studies
justify further analysis of Nuc-Stat5a as a potentially
clinically useful measurement of response to antiestro-
gen therapy.
Discussion
The present study used quantitative in situ analysis to
reveal for the first time a significant reduction in total
cellular and nuclear Stat5a protein levels in invasive
breast cancer and lymph node metastases compared
with normal breast epithelia and DCIS. In contrast,
Stat5b protein levels remained unchanged, suggesting
divergent expression and involvement of Stat5a and
Stat5b during breast cancer progression. Consistent with
the notion of distinct roles in human breast cancer,
experimental hyperactivation of transcription factors
Stat5a or Stat5b independently in MCF-7 breast cancer
cells revealed only limited overlap between Stat5a- and
Stat5b-responsive genes. Likewise, low mRNA expres-
sion for Stat5a but not Stat5b correlated with poor
prognosis in a cohort of more than 900 patients. In situ
analysis of two separate cohorts totaling more than 500
patients with therapy-naïve, lymph node-negative breast
cancer identified low levels of nuclear localized Stat5a
(Nuc-Stat5a) protein as an independent marker of poor
prognosis. In both of these patient cohorts, reduced
levels of Nuc-Stat5a protein were associated with greater
than twofold increased risk of death of breast cancer
after adjustment for other clinical parameters in multi-
variate analyses.
Analysis of tumors from a second pair of independent
cohorts of patients, who had received adjuvant antiestro-
gen monotherapy, identified loss of Nuc-Stat5a protein
as an independent marker associated with greater than
fourfold increased risk of death from breast cancer in
this population.
A general shortcoming of previous studies of Stat5
expression in breast cancer has been the lack of analytic
distinction of Stat5a from the highly homologous Stat5b.
Our novel observations suggest a selective loss of Stat5a
protein during breast cancer progression, representing a
newly defined mechanism to explain partially the
observed frequent loss of Nuc-pYStat5a/b during breast
cancer progression [29,30]. Alternative but not mutually
exclusive mechanisms recently reported include disrup-
tion of Stat5a/b phosphorylation during breast cancer
progression through upregulation of the Jak2 tyrosine
phosphatase, PTP1B [43], or inhibitory signaling to Stat5
by the truncated ERBB2 isoform, p100-t-ERBB2 [45].
Importantly, loss of Stat5a protein may also be a conse-
quence of reduced Stat5a activation because numerous
putative Stat5a response elements occur within the
Stat5a gene promoter [46], a possibility that will be
explored in future studies.
The favorable prognosis associated with continued
expression and nuclear localization of Stat5a in invasive
breast cancer supports the hypothesis drawn from in
vitro studies that, despite a potential role in tumor initia-
tion, Stat5a signaling is important for maintaining tumor
differentiation and suppressing disease progression in
established human breast cancer [11,12,20,21]. Interest-
ingly, the transcription factor NFAT1 exerts actions
opposite to Stat5 in breast cancer by inhibiting tumor
growth while promoting metastasis [47,48]. NFAT1
Table 3 Univariate and multivariate Cox regression survival analysis of breast cancer-specific survival (CSS) and time
to recurrence (TTR) as a function of Nuc-Stat5a in breast cancer patients treated with antiestrogen monotherapy
(Materials V and VI) (Continued)
Pos 47 0.51 (0.17 to 1.48) 0.214 0.30 (0.13 to 0.68) 0.004
Her2 status Neg 48 1 - 1 -
Pos 7 3.35 (1.13 to 9.93) 0.029 3.06 (1.24 to 7.56) 0.015
Stat5a Low (< 1,454) 16 2.14 (0.89 to 5.12) 0.087 2.15 (1.06 to 4.35) 0.033
High (≥1,454) 39 1 - 1 -
Global test for PH assumption: c2(6) = 4.67; P = 0.59. CI, confidence interval; ER/PR status, estrogen or progesterone receptor positive; HR, hazard ratio; LN status,
lymph node status.
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displayed reciprocal negative crosstalk with Stat5, and
NFAT levels were inversely correlated with Stat5 levels in
human breast cancer [49]. Additionally, the new outcome
data help clarify previous immunohistochemical reports
documenting prognostic and antiestrogen response-pre-
dictive associations of nuclear localized, tyrosine phos-
phorylated Stat5a/b (Nuc-pYStat5a/b) [29,30] or cellular
Stat5 [31]. Considering that as many as one third of
patients with ER-positive breast cancer develop resistance
to antiestrogen therapy and relapse [50,51], identification
of patients with increased risk of therapy failure for stra-
tification into more aggressive therapies is also essential.
Many strategies have been proposed to identify patients
with therapy-resistant tumors, including PCR-based
assays, gene-expression profiling, or immunohistochem-
ical detection of biomarkers such as Her2, EGFR, IGF-IR,
PR, p27, AIB1, IRS-1, caveolin-1, retinoblastoma tumor
suppressor, and nuclear localized and tyrosine phos-
phorylated Stat5a/b [30,38,51-55]. Interestingly, Nuc-
Stat5a remained an independent marker of prognosis and
response to antiestrogen therapy when other putative
markers of antiestrogen responsiveness, such as Her2
(Table 3), PR (Table 3) or Ki67 (data not shown), were
included in multivariate analyses, and levels of Nuc-
Stat5a did not correlate with Her2 or Ki67 expression
(data not shown). Molecular mechanistic studies in vivo
will be needed to determine whether causal mechanisms
exist by which Stat5a affects tumor responsiveness to
antiestrogen therapy.
Although the new data provide clarity about Stat5a and
Stat5b in breast cancer, several limitations of this study
exist. The present study focused on Stat5a and Stat5b
expression in normal and malignant cells, but it will be
important in future work to include analyses of expression
of Stat5a and Stat5b in stromal tumor cells. A combina-
tion of quantitative analysis of fluorescent immunolabeling
and standard pathologist-based scoring of DAB-chromo-
gen staining was used. More robust data will come from
future inclusion of additional cases and further standar-
dized assay conditions, including development of assays
for absolute quantification of Stat5a and Stat5b proteins in
cellular compartments within the tumors, as has been
achieved for other proteins [56]. Furthermore, optimal
cutpoints for high and low Stat5a, derived by an objective
method (R statistical software), differed between the
cohorts, at least in part because of different analytic meth-
ods. However, clinically relevant Stat5a levels may differ
between prognostic and antiestrogen therapy-response
outcomes, as Stat5a may have distinct biologic functions
relevant for each of the two clinical outcomes. Our
cohorts were of limited size, and partial loss of evaluable
tissues on the tissue microarrays and missing or incom-
plete clinical data for some of the parameters reduced the
statistical power of some multivariate analyses. For
instance, despite a strong predictive association of Nuc-
Stat5a in CSS analyses in Material VI, TTR in Material VI
failed to reach statistical significance by univariate log-
rank (P = 0.11) and multivariate Cox regression models (P
= 0.087), whereas univariate Cox regression in Material VI
indicated a twofold significant increased risk of breast can-
cer recurrence (P = 0.033). This discrepancy could be a
result of limited numbers of cases or reflect that data may
not be missing at random, although specific patterns
within missing data did not emerge within any cohort of
patients examined in this study (data not shown).
It is perhaps surprising that tumor grade was not signifi-
cant in univariate or multivariate analyses in the cohorts
of this study, given evidence for prognostic association
with histologic grade in breast cancer [57]. However, lack
of detectable prognostic value of breast cancer grade is not
uncommon [58,59] and may, at least in part, result from
variable tissue handling and tumor grading between differ-
ent pathologists, particularly because many of the tumor
samples analyzed were obtained prior to the 1990s, when
the importance of uniform grading systems became appar-
ent and were adopted [57].
Finally, analyses were confined to retrospective
cohorts and the antiestrogen predictive analyses must be
followed up with studies of randomized prospective trial
materials.
Conclusions
Total Stat5a protein, as well as nuclear localization of
Stat5a, is frequently lost in invasive breast cancer and
lymph node metastases. Reduced levels of Nuc-Stat5a
were associated with a more than twofold increased risk
of unfavorable outcome in multivariate analyses of two
independent cohorts of node-negative breast cancer, and
may therefore represent a novel strong prognostic mar-
ker [60]. Furthermore, low levels of Nuc-Stat5a were
associated with a more than fourfold increased risk of
unfavorable outcome in multivariate analyses of two
independent cohorts of patients treated with antiestro-
gen monotherapy. Low levels of Nuc-Sta5a therefore
hold potential to become a new predictive marker of
resistance to antiestrogen therapy, provided that the
relation can be validated in clinical trial cohorts of
patients randomized for antiestrogen therapy.
Additional material
Additional file 1: Specificity of Stat5a and Stat5b polyclonal
antibodies. (A) Immunoprecipitation of Stat5a (94 kDa) or Stat5b (92
kDa) protein from SKBR3 breast cancer cells, followed by immunoblotting
with the Stat5a, Stat5b, or a pan-Stat5a/b antibody, revealed specificity
and lack of cross-reactivity between Stat5a and Stat5b antibodies. (B)
Specificity of Stat5a and Stat5b antibodies in formalin-fixed, paraffin-
embedded breast tissue was verified by using a blocking peptide assay.
Antibodies were preincubated with the respective immunizing peptide
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or control before performing standard immunohistochemistry.
Representative images from adjacent sections of the same tissues are
shown.
Additional file 2: Adenoviral expression and prolactin-induced
phosphorylation of Stat5a and Stat5b in MCF7 human breast
cancer cells lines. MCF7 cells were infected with adenovirus (MOI 40)
expressing Stat5a or Stat5b and stimulated with prolactin for 20 minutes.
Endogenous Stat5a and Stat5b were not detected with Western blot of
whole-cell lysates from control cells, and phosphorylation of Stat5 was
not detected in the absence of prolactin in control or Stat5a/Stat5b-
overexpressing cells.
Additional file 3: Stat5a- and Stat5b-mediated genes. List of 150
genes most significantly regulated by Stat5a or Stat5b in response to
prolactin in MCF7 human breast cancer cell lines. *Genes modulated in
common by Stat5a and Stat5b. FDR, false discovery rate.
Additional file 4: Univariate and multivariate Cox regression
survival analyses of time to recurrence (TTR) of breast cancer in
Material III. CI, confidence interval; ER. estrogen receptor; HR, hazard
ratio; PR, progesterone receptor.
Abbreviations
AQUA: Automated quantitative analysis; CI: confidence interval; CSS: breast
cancer-specific survival; DAB-IHC: DAB-chromogen immunohistochemistry;
DCIS: ductal carcinoma in situ; ER: estrogen receptor; FDR: false discovery
rate; HR: hazard ratio; IDC: invasive ductal carcinoma; IQR: interquartile range;
LN: lymph node; LN Met: lymph node metastasis; Nuc-pYStat5a/b: nuclear
localized and tyrosine phosphorylated Stat5a/b; Nuc-Stat5a: nuclear localized
Stat5a; Nuc-Stat5b: nuclear localized Stat5b; PR: progesterone receptor; SD:
standard deviation; Stat5a: signal transducer and activator of transcription-5a;
Stat5b: signal transducer and activator of transcription-5b; TTR: time to
breast cancer recurrence.
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